Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Roddie

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Scientific Reports|November 6, 2020
A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised ratsFrancesco Nannini, Farhaan Parekh, Patrycja Wawrzyniecka, et al.
European Journal of Haematology|December 11, 2024
The Effect of the Pre-Transplant Disease Status on the Outcome for Recipients of T-Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell LymphomasMaria A V Marzolini, Irfan Kayani, Ben Carpenter, et al.
Transplantation and Cellular Therapy|August 26, 2023
Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter StudyAlexandros Rampotas, Katja Sockel, Fotios Panitsas, et al.
Journal for Immunotherapy of Cancer|September 14, 2023
AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survivalVedika Mehra, Giulia Agliardi, Juliana Dias Alves Pinto, et al.
The Journal of Experimental Medicine|July 31, 2013
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaTyler R Simpson, Fubin Li, Welby Montalvo-Ortiz, et al.
Ejhaem|July 18, 2022
Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case reportStrachan Mackenzie, Manar Shafat, Harriet Roddy, et al.
Blood Advances|February 1, 2023
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphomaClaire Roddie, Lorna Neill, Wendy Osborne, et al.
Scientific Reports|November 10, 2021
Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interactionAlastair Hotblack, Evangelia K Kokalaki, Morgan J Palton, et al.
Bone Marrow Transplantation|April 9, 2025
Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines CommitteeGuillermo Ortí, Guillaume Dachy, Charlotte E Graham, et al.
Haematologica|January 8, 2026
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Karamjeet S Sandhu, Paul Shaughnessy, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Scientific Reports|November 6, 2020
A primer set for the rapid isolation of scFv fragments against cell surface antigens from immunised ratsFrancesco Nannini, Farhaan Parekh, Patrycja Wawrzyniecka, et al.
European Journal of Haematology|December 11, 2024
The Effect of the Pre-Transplant Disease Status on the Outcome for Recipients of T-Cell Depleted Allogeneic Haematopoietic Stem Cell Transplants for Large B Cell LymphomasMaria A V Marzolini, Irfan Kayani, Ben Carpenter, et al.
Transplantation and Cellular Therapy|August 26, 2023
Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter StudyAlexandros Rampotas, Katja Sockel, Fotios Panitsas, et al.
Journal for Immunotherapy of Cancer|September 14, 2023
AKT inhibition generates potent polyfunctional clinical grade AUTO1 CAR T-cells, enhancing function and survivalVedika Mehra, Giulia Agliardi, Juliana Dias Alves Pinto, et al.
The Journal of Experimental Medicine|July 31, 2013
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanomaTyler R Simpson, Fubin Li, Welby Montalvo-Ortiz, et al.
Ejhaem|July 18, 2022
Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case reportStrachan Mackenzie, Manar Shafat, Harriet Roddy, et al.
Blood Advances|February 1, 2023
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphomaClaire Roddie, Lorna Neill, Wendy Osborne, et al.
Scientific Reports|November 10, 2021
Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interactionAlastair Hotblack, Evangelia K Kokalaki, Morgan J Palton, et al.
Bone Marrow Transplantation|April 9, 2025
Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines CommitteeGuillermo Ortí, Guillaume Dachy, Charlotte E Graham, et al.
Haematologica|January 8, 2026
Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Karamjeet S Sandhu, Paul Shaughnessy, et al.
Pageof 7